论文部分内容阅读
目的:探讨转移抑制因子1(MTSS1)在胆管细胞癌组织中的表达及临床意义。方法:前瞻性收集2012年1月—2014年1月收治的89例胆管细胞癌患者作为研究组,同时收集因胆结石行胆囊切除的患者89例作为对照组。比较两组患者病理组织中MTSS1表达的差异,并进一步分析MTSS1与胆囊癌患者临床病理因素及预后的关系。结果:与对照组比较,研究组患者MTSS1阳性率明显降低(20.22%vs.58.43%,P=0.000),MTSS1阳性细胞百分比显明降低(9.47%vs.43.95%,P=0.000)。与MTSS1阳性的胆管细胞癌患者比较,MTSS1阴性者肿瘤大小明显增加(3.84 cm vs.2.46 cm,P=0.000)、肿瘤分期为III或IV期的患者比例明显上升(70.42%vs.27.78%,P=0.001)、淋巴结转移率明显增加(77.46%vs.44.44%,P=0.028)、2年内病死率明显增高(42.25%vs.16.67%,P=0.045)、肿瘤细胞为低分化者明显增加(P=0.001)。Logistic回归分析显示MTSS1阴性是胆管细胞癌患者死亡的独立危险因素(P=0.000),Wilcoxon检验显示MTSS1阳性患者生存率明显高于MTSS1阴性的患者(P=0.041)。结论:MTSS1表达下降或缺失与胆管细胞癌的发生和发展密切相关。
Objective: To investigate the expression of metastasis suppressor 1 (MTSS1) in cholangiocarcinoma and its clinical significance. Methods: A total of 89 patients with cholangiocarcinoma who were admitted to our hospital from January 2012 to January 2014 were prospectively enrolled. A total of 89 patients with gallbladder resection due to gallstones were selected as the control group. The differences of MTSS1 expression in pathological tissues between the two groups were compared, and the relationship between MTSS1 and the clinicopathological factors and prognosis of gallbladder carcinoma was further analyzed. Results: Compared with the control group, the positive rate of MTSS1 in study group was significantly lower (20.22% vs.58.43%, P = 0.000), and the percentage of MTSS1 positive cells was significantly lower (9.47% vs.43.95%, P = 0.000). Compared with patients with MTSS1-positive cholangiocarcinoma, the tumor size was significantly increased in MTSS1-negative patients (3.84 cm vs.2.46 cm, P = 0.000). The proportion of patients with stage III or IV tumors was significantly increased (70.42% vs.27.78% P = 0.001). The rate of lymph node metastasis was significantly increased (77.46% vs.44.44%, P = 0.028). The mortality was significantly higher in two years (42.25% vs.16.67%, P = 0.045) (P = 0.001). Logistic regression analysis showed that MTSS1 negative was an independent risk factor for death from cholangiocarcinoma (P = 0.000). The Wilcoxon test showed that the survival rate of MTSS1 positive patients was significantly higher than that of MTSS1 negative patients (P = 0.041). Conclusion: The decrease or deletion of MTSS1 expression is closely related to the occurrence and development of cholangiocarcinoma.